In reply: Factor VIII inhibitor and source of replacement therapy

Blood Transfusion

Volumn 10, Issue 1, 2012, Pages 112-113

  Mannucci, Pier O ^a   Gringeri, Alessandro ^a   Santagostino, Elena ^a   Peyvandi, Flora ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

HEMOPHILIA A; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LETTER; MEDICAL DECISION MAKING; PATIENT CARE; VIRUS INFECTION; BLOODBORNE BACTERIUM; FEMALE; MALE; NOTE; VIRUS INACTIVATION;

BLOOD-BORNE PATHOGENS; FACTOR VIII; FEMALE; HEMOPHILIA A; HUMANS; MALE; VIRUS DISEASES; VIRUS INACTIVATION;

EID: 84855728105     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0064-11     Document Type: Letter

References (13)

1. Calizzani G, Arcieri R. Clinical and organizational aspects of hemophilia care: the patient's view. Blood Transfus 2012; 10: 110-1.
2. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. Blood Transfus 2010; 8: 288-91.
3. Franchini M. Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-96.
4. Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011; 9: 366-70.
5. Iorio A, Halimeh S, Holzhauer S et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
6. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl 5): 65-8. (Pubitemid 350253407)
7. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
8. Scharrer I, Ehrlich HJ. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia 2001; 7: 346-8. (Pubitemid 32677651)
9. Rubinger M, Lillicrap D, Rivard GE, et al. for the Association of Hemophilia Clinic Directors of Canada. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-6. (Pubitemid 351338688)
10. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003; 9: 405-17. (Pubitemid 36874390)
11. Howard TE, Yanover C, Mahlangu J, et al. Haemophilia management: time to get personal? Haemophilia 2011; DOI: 10.1111/j.1365-2516.2011.02517.x.
12. Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 (Suppl 2): S22-5.
13. Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T. Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J Thromb Haemost 2007; 5: 901-6. (Pubitemid 46691717)